Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

PMID:
31484791
2.

Telemedicine-Assisted Self-Management Program for Type 2 Diabetes Patients.

von Storch K, Graaf E, Wunderlich M, Rietz C, Polidori MC, Woopen C.

Diabetes Technol Ther. 2019 Sep;21(9):514-521. doi: 10.1089/dia.2019.0056. Epub 2019 Jul 9.

PMID:
31287736
3.

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C, Han L, Zhu Z, Lian F, Wei J, Deng Q, Wang Y, Wunderlich M, Gao Z, Pan G, Zhong D, Zhou H, Zhang N, Gan J, Jiang H, Mulloy JC, Qian Z, Chen J, Yang CG.

Cancer Cell. 2019 Apr 15;35(4):677-691.e10. doi: 10.1016/j.ccell.2019.03.006.

PMID:
30991027
4.

Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial.

Karstens S, Krug K, Raspe H, Wunderlich M, Hochheim M, Joos S, Hüppe A.

BMC Musculoskelet Disord. 2019 Feb 28;20(1):94. doi: 10.1186/s12891-019-2467-6.

5.

Endogenous IL-22 is dispensable for experimental glomerulonephritis.

Gnirck AC, Wunderlich M, Becker M, Xiong T, Weinert E, Meyer-Schwesinger C, Dumoutier L, Renauld JC, Huber S, Panzer U, Turner JE.

Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F712-F722. doi: 10.1152/ajprenal.00303.2018. Epub 2019 Feb 6.

PMID:
30724106
6.

Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Wunderlich M, Chou FS, Sexton C, Presicce P, Chougnet CA, Aliberti J, Mulloy JC.

PLoS One. 2018 Dec 12;13(12):e0209034. doi: 10.1371/journal.pone.0209034. eCollection 2018.

7.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ.

Exp Hematol. 2018 Nov;67:18-31. doi: 10.1016/j.exphem.2018.08.004. Epub 2018 Aug 17.

PMID:
30125602
8.

A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells.

Du W, Liu W, Mizukawa B, Shang X, Sipple J, Wunderlich M, Geiger H, Davies S, Mulloy J, Pang Q, Zheng Y.

Leukemia. 2018 Sep;32(9):2041-2046. doi: 10.1038/s41375-018-0200-3. Epub 2018 Jun 29. No abstract available.

9.

A novel approach to support formulation design on twin screw wet granulation technology: Understanding the impact of overarching excipient properties on drug product quality attributes.

Willecke N, Szepes A, Wunderlich M, Remon JP, Vervaet C, De Beer T.

Int J Pharm. 2018 Jul 10;545(1-2):128-143. doi: 10.1016/j.ijpharm.2018.04.017. Epub 2018 Apr 21.

PMID:
29684559
10.

T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.

Düster M, Becker M, Gnirck AC, Wunderlich M, Panzer U, Turner JE.

Eur J Immunol. 2018 Aug;48(8):1364-1375. doi: 10.1002/eji.201747303. Epub 2018 May 17.

11.

Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192.

12.

Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach.

Haase R, Wunderlich M, Dillenseger A, Kern R, Akgün K, Ziemssen T.

Expert Opin Drug Saf. 2018 Apr;17(4):369-378. doi: 10.1080/14740338.2018.1437144. Epub 2018 Feb 13. Review.

PMID:
29436244
13.

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2018 Feb 9;9(1):670. doi: 10.1038/s41467-018-02947-0.

14.

Evaluation of Predictive Factors for Successful Intravitreal Dexamethasone in Pseudophakic Cystoid Macular Edema.

Kakkassery V, Schultz T, Wunderlich MI, Schargus M, Dick HB, Rehrmann J.

J Ophthalmol. 2017;2017:4625730. doi: 10.1155/2017/4625730. Epub 2017 Dec 19.

15.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification.

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J.

Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.

16.

[Evaluation of a Proactive Health Programme for Insured Persons with Persistent Back Pain: One-year Follow-up of a Randomised Controlled Trial].

Hüppe A, Wunderlich M, Hochheim M, Mirbach A, Zeuner C, Raspe H.

Gesundheitswesen. 2017 Dec 18. doi: 10.1055/s-0043-121696. [Epub ahead of print] German.

PMID:
29253915
17.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J.

Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.

18.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w. Erratum in: Nat Commun. 2018 Feb 9;9(1):670.

19.

Typology of Uncertainty in Static Geolocated Graphs for Visualization.

von Landesberger T, Bremm S, Wunderlich M.

IEEE Comput Graph Appl. 2017;37(5):18-27. doi: 10.1109/MCG.2017.3621220.

PMID:
28945576
20.

Cross-Species Y Chromosome Function Between Malaria Vectors of the Anopheles gambiae Species Complex.

Bernardini F, Galizi R, Wunderlich M, Taxiarchi C, Kranjc N, Kyrou K, Hammond A, Nolan T, Lawniczak MNK, Papathanos PA, Crisanti A, Windbichler N.

Genetics. 2017 Oct;207(2):729-740. doi: 10.1534/genetics.117.300221. Epub 2017 Aug 31.

21.

Murine Roseolovirus, Historically Known as Murine Thymic Lymphotropic Virus.

Wang C, Wunderlich M, Henderson K.

J Virol. 2017 Aug 24;91(18). pii: e00943-17. doi: 10.1128/JVI.00943-17. Print 2017 Sep 15. No abstract available.

22.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Mizukawa B, O'Brien E, Moreira DC, Wunderlich M, Hochstetler CL, Duan X, Liu W, Orr E, Grimes HL, Mulloy JC, Zheng Y.

Blood. 2017 Sep 14;130(11):1336-1346. doi: 10.1182/blood-2016-12-758458. Epub 2017 Aug 4.

23.

CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium.

Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Jian G, Engevik AC, Yang L, Wang J, Goldenring JR, Qualls JE, Medvedovic M, Helmrath MA, Diwan T, Mulloy JC, Zavros Y.

J Pathol. 2017 Aug;242(4):463-475. doi: 10.1002/path.4918.

24.

Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma.

Kakkassery V, Schroers R, Coupland SE, Wunderlich MI, Schargus M, Heinz C, Wasmuth S, Heiligenhaus A, Ahle G, Lenoble P, Schlegel U, Schmiegel W, Dick HB, Baraniskin A.

Blood. 2017 Jun 8;129(23):3130-3133. doi: 10.1182/blood-2017-01-765180. Epub 2017 Apr 7. No abstract available.

25.

Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.

Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, Guan JL, Mulloy JC, Kumar A, Zheng Y.

Autophagy. 2017 May 4;13(5):955-966. doi: 10.1080/15548627.2017.1287652. Epub 2017 Feb 15.

26.

Identifying overarching excipient properties towards an in-depth understanding of process and product performance for continuous twin-screw wet granulation.

Willecke N, Szepes A, Wunderlich M, Remon JP, Vervaet C, De Beer T.

Int J Pharm. 2017 Apr 30;522(1-2):234-247. doi: 10.1016/j.ijpharm.2017.02.028. Epub 2017 Feb 14.

PMID:
28213278
27.

[Macrophages : Causing ocular metastasis or immune reaction on tumor cells in the eye?]

Wunderlich MI, Nissen EJ, Schargus M, Dick HB, Pohl M, Coupland SE, Kakkassery V.

Ophthalmologe. 2016 Dec;113(12):1092-1094. German. No abstract available.

PMID:
27888302
28.

Online measurement of viscosity for biological systems in stirred tank bioreactors.

Schelden M, Lima W, Doerr EW, Wunderlich M, Rehmann L, Büchs J, Regestein L.

Biotechnol Bioeng. 2017 May;114(5):990-997. doi: 10.1002/bit.26219. Epub 2016 Nov 21.

PMID:
27861738
29.

Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.

Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ.

Cancer Cell. 2016 Nov 14;30(5):737-749. doi: 10.1016/j.ccell.2016.10.008.

30.

MISTRG extends PDX modeling to favorable AMLs.

Wunderlich M, Mulloy JC.

Blood. 2016 Oct 27;128(17):2111-2112. No abstract available.

31.

[Ocular Lymphomas].

Kakkassery V, Wunderlich MI.

Klin Monbl Augenheilkd. 2016 Oct;233(10):1175-1191. Epub 2016 Aug 5. Review. German. No abstract available.

PMID:
27494680
32.

A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC.

JCI Insight. 2016 Sep 22;1(15):e88181. doi: 10.1172/jci.insight.88181.

33.

Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.

Lin S, Wei J, Wunderlich M, Chou FS, Mulloy JC.

Oncotarget. 2016 Aug 30;7(35):55939-55950. doi: 10.18632/oncotarget.11093.

34.

Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9075-80. doi: 10.1073/pnas.1524225113. Epub 2016 Jul 25.

35.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. Epub 2015 Dec 17.

36.

[Unusual masquerade of an ocular carcinoma metastasis].

Wunderlich MI, Nissen EJ, Schargus M, Dick HB, Pohl M, Coupland SE, Kakkassery V.

Ophthalmologe. 2016 Aug;113(8):690-3. doi: 10.1007/s00347-015-0165-9. German.

PMID:
26621346
37.

A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds.

Thowfeik FS, AbdulSalam SF, Wunderlich M, Wyder M, Greis KD, Kadekaro AL, Mulloy JC, Merino EJ.

Chembiochem. 2015 Nov;16(17):2513-21. doi: 10.1002/cbic.201500304. Epub 2015 Nov 2.

38.

Does Bilateral ITA Grafting Increase Perioperative Complications? Outcome of 6,476 Patients with Bilateral versus 5,020 Patients with Single ITA Bypass.

Deutsch O, Gansera L, Wunderlich M, Eichinger W, Gansera B.

Thorac Cardiovasc Surg. 2016 Apr;64(3):188-94. doi: 10.1055/s-0035-1558992. Epub 2015 Aug 13.

PMID:
26270198
39.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91. doi: 10.1073/pnas.1422749112. Epub 2015 Aug 10.

40.

Xenograft models for normal and malignant stem cells.

Goyama S, Wunderlich M, Mulloy JC.

Blood. 2015 Apr 23;125(17):2630-40. doi: 10.1182/blood-2014-11-570218. Epub 2015 Mar 11. Review.

41.

MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.

Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR.

Blood. 2015 Apr 16;125(16):2544-52. doi: 10.1182/blood-2014-09-599258. Epub 2015 Mar 4.

42.

Quantifying the sensitivity of G. oxydans ATCC 621H and DSM 3504 to osmotic stress triggered by soluble buffers.

Luchterhand B, Fischöder T, Grimm AR, Wewetzer S, Wunderlich M, Schlepütz T, Büchs J.

J Ind Microbiol Biotechnol. 2015 Apr;42(4):585-600. doi: 10.1007/s10295-015-1588-7. Epub 2015 Feb 3.

PMID:
25645092
43.

Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells.

Vadukoot AK, AbdulSalam SF, Wunderlich M, Pullen ED, Landero-Figueroa J, Mulloy JC, Merino EJ.

Bioorg Med Chem. 2014 Dec 15;22(24):6885-92. doi: 10.1016/j.bmc.2014.10.029. Epub 2014 Oct 30.

44.

Heat shock factor HSFB2a involved in gametophyte development of Arabidopsis thaliana and its expression is controlled by a heat-inducible long non-coding antisense RNA.

Wunderlich M, Gross-Hardt R, Schöffl F.

Plant Mol Biol. 2014 Aug;85(6):541-50. doi: 10.1007/s11103-014-0202-0. Epub 2014 May 30.

45.

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J.

J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.

46.

OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC.

Blood. 2014 Jun 12;123(24):e134-44. doi: 10.1182/blood-2014-02-556340. Epub 2014 Apr 28.

47.

Plasma antibody profiles in non-human primate tuberculosis.

Ravindran R, Krishnan VV, Dhawan R, Wunderlich ML, Lerche NW, Flynn JL, Luciw PA, Khan IH.

J Med Primatol. 2014 Apr;43(2):59-71. doi: 10.1111/jmp.12097. Epub 2014 Jan 22.

PMID:
24446897
48.

Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL.

J Clin Invest. 2014 Jan;124(1):222-36. doi: 10.1172/JCI66005. Epub 2013 Dec 16.

49.

An MDS xenograft model utilizing a patient-derived cell line.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT.

Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11. No abstract available.

50.

Effect of growth rate on plasmid DNA production and metabolic performance of engineered Escherichia coli strains.

Wunderlich M, Taymaz-Nikerel H, Gosset G, Ramírez OT, Lara AR.

J Biosci Bioeng. 2014 Mar;117(3):336-42. doi: 10.1016/j.jbiosc.2013.08.007. Epub 2013 Sep 5.

PMID:
24012107

Supplemental Content

Loading ...
Support Center